|
AMIODARONE INHIBITS CYP2D6 ; DEXTROMETHORPHAN IS A SUBSTRATE FOR BOTH CYP2D6 AND CYP3A4 ; CHRONIC (> 2 WEEKS) ORAL AMIODARONE ADMINISTRATION IMPAIRS DEXTROMETHORPHAN METABOLISM
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
METOCLOPRAMIDE EFFECTS ON G.I. MOTILITY ARE ANTAGONISED BY THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS LIKE NIALAMIDE MAY BE ASSOCIATED WITH SEVERE & SOMETIMES FATAL REACTIONS & IS NOT RECOMMENDED
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|